The GHDC (Glyoxalase Domain Containing) antibody is a tool used to study the GHDC protein, which belongs to the glyoxalase enzyme family involved in detoxifying methylglyoxal (MG), a reactive byproduct of glycolysis. Elevated MG levels are linked to oxidative stress, diabetes, and age-related diseases. GHDC shares structural homology with glyoxalase 1 (GLO1) but exhibits distinct catalytic properties and tissue expression patterns. Research suggests GHDC may play roles in cellular metabolism, redox balance, and cancer progression, though its precise biological functions remain under investigation.
Developed for both basic and clinical research, GHDC antibodies are primarily utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression and localization. Studies have explored its overexpression in certain cancers (e.g., breast, liver) and its potential as a biomarker or therapeutic target. Commercial GHDC antibodies are typically raised against specific epitopes, often validated for cross-reactivity in human, mouse, or rat samples. Recent interest in metabolic dysregulation and carbonyl stress has amplified its relevance in studying neurodegenerative diseases, diabetic complications, and tumor microenvironments. However, standardized functional characterization and disease-specific pathways require further elucidation.